CNTX-6970 is under clinical development by Centrexion Therapeutics and currently in Phase II for Osteoarthritis Pain. According to GlobalData, Phase II drugs for Osteoarthritis Pain have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CNTX-6970’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CNTX-6970 overview
CNTX-6970 is under development for the treatment of knee osteoarthritis pain. The drug candidate is administered orally. It is a small molecule that acts by targeting the cytokine CCR2 (C-C Chemokine receptor type 2).
See Also:
Centrexion Therapeutics overview
Centrexion Therapeutics is a clinical-stage biopharmaceutical company. It identifies, develops and commercializes novel, non-opioid and non-addictive therapies for the treatment of chronic pain. The company’s pipeline products include CNTX-4975, CNTX- 0290, CNTX-6970, CNTX-2022, and CNTX-6016 which are related to the treatment of human osteoarthritis pain, inflammatory pain, superficial pain, chronic, neuropathic pain and other pains. Centrexion Therapeutics develops drugs in the form of topical gel, joint or deeper tissue injection, spinal delivery and three separate oral therapies. The company works in partnership with other companies in the field of big data analytics and artificial intelligence to advance its pipeline products. Centrexion Therapeutics is headquartered in Boston, Massachusetts, the US.
For a complete picture of CNTX-6970’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
